While treatment strategies targeting pro-inflammatory cytokines such as IL-6 were studied to be effective in TB-IRIS patients, there is no evidence of IL-6 inhibitors being effective against severe COVID-19 [3,128]. Here, IL6 is linked to tuberculosis.